(firstQuint)Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance.

 The objective of this study is to estimate the median progression -free survival for patients receiving this regimen, along with the rate of complete response at 6 months, toxicities associated with this regimen, and laboratory correlates.

 Subjects will receive the Zevalin(Ibritumomab Tiuxetan) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression.

.

 Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance@highlight

Subjects will receive the Zevalin(Ibritumomab Tiuxetan) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression